Evaluation of alternative radionuclides for use in prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) is currently focusing on Terbium-161, which may provide advantages by emitting additional Auger and conversion electrons. In this pilot study, we present preliminary dosimetry data for [Terbium-161]Tb-PSMA-617 RLT in a direct comparison with [Lutetium-177]Lu-PSMA-617.
[Terbium-161] Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [Lutetium-177]Lu-PSMA-617
By Torpedo / 10th April, 2025
